BioSpace News Archive

Fluidigm Corporation announced that a consortium of medical schools led by the Icahn School of Medicine at Mount Sinai is utilizing Fluidigm® microfluidics technology to create an epigenetic test for early detection of the novel coronavirus that causes COVID-19.

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. today announced that it has dosed the first patient in its KIK-AS ( K nockdown of UBE3A -antisense i n K ids with A ngelman S yndrome ) study of GTX-102, an experimental antisense oligonucleotide being evalu

Community clinics can access same medical record data as hospital participants to close gaps for underserved patients in Los Angeles County

Global Mobility Solutions, the industry leader in corporate relocation services and technology, is proud to announce it has achieved Top 3 ranking on HRO Today’s 2020 Baker’s Dozen Customer Satisfaction Survey.

Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) based in Shenzhen, and focused on Aesthetic Medical Services, today announced that Chief Strategy Officer, Mr. Andrew Fan, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on March 18.

Merck KGaA invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced a corporate update highlighting the continued commercial progress of its RadioGenix® System (technetium Tc 99m generator).

Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that Propanc’s Scientific Advisory Board member and Lead Researcher, Dr Macarena Perán from Jaén University, Spain was recently promoted to a Professorship position at her University. This press release feat

Spero Therapeutics, Inc. today announced financial results for the fourth quarter and full-year ended December 31, 2019 and provided a pipeline update.

Arcutis Biotherapeutics, Inc. announced that, at the request of the U.S. Food and Drug Administration, Arcutis has submitted a protocol amendment to the FDA to include children ages 2 to 11 years old in the Company’s on-going DERMIS-1 and DERMIS-2 pivotal Phase 3 clinical trials evaluating topical roflumilast cream as a potential topical treatment for plaque psoriasis.